DexCom Expands FDA-Cleared Use of Stelo Glucose Biosensor for Children
DexCom, Inc. (DXCM) announced that the U.S. Food and Drug Administration has cleared its Stelo glucose biosensor for use in children aged 2 years or older who do not require insulin therapy. The company also plans to launch a redesigned app with enhanced features starting this July and expand into international markets later this year.
Tickers: $DXCM